had HEPZATO candidate late you, joining of the move CHEMOSAT, the company's Thank for very investigational KIT, both XXXX we Delcath product productive the this quarter quarter. U.S., a drug new the for year-to-date, the to KIT and a United States; towards for continue in product today. the In second marketed in company's Europe. HEPZATO forward resubmission of and the application everyone, has
with and previously in of interaction resubmission late hand. feedback with FDA, As in reported, completed barriers no that provided the current FDA, NDA by the based and we subsequent on April, meeting and a pre-NDA meeting minutes to incorporated a we see recommendations, data which
Trial purposes and considered FOCUS queries resolved the For and are the have has of locked. complete, been submission, been NDA all database
agree expect from if will, they fully is we receipt a will resubmission, the and Within of date establish the submissions. future locked database of event the and FDA continue submission, mid-XXXX. purposes of endpoints Delcath to to such mature is will data with FDA six PDUFA the we submission expect that updates the While to after complete I submission, to and provide they overall additional expects through times the which want certain review, for XX-days remind routine months date. survival confirm these warrant sufficiently submission as periodic listeners the
The foundation an FDA review take Committee, in one Advisory time June. of While for are do FOCUS I and the the opportunity for is updated data which safety. benefits Annual to resubmission we consistent HEPZATO’s in those believe Lead from the to Global that Zeiger, Dr. not NDA update clinically efficacy traditional covered preparing to Trial look during produces that ASCO's results, have forward Jonathan Investigator, release. know an with will will will with the provided whether highlight Meeting efficacy convene to patients we HEPZATO cytotoxics. we the and safety data suffering profile is reiterate line early I of data the here liver-dominant since was forms demonstrate and other metastatic totality data I that the times largely meaningful that the and ocular many the its various simply in melanoma
the very data profile ensure access we the patients. and program patients opening review, we access FDA have together, KIT have started NDA positive suitable expanded an In believe Taken or sites. the effort HEPZATO supports risk for to a during to preparation benefit EAP
treatment patients three refer three schedule treatments have this treating to to-date The will and pace completed increase first The treatments sites. the opened month. another of site has more as
The second until October patients, coordinator due start issues. but screen site treating has trial clinical may not to started staffing to
We the reduce sites pace judicious to of will and opening EAP in prepared. treating sites our qualified well are ensure
to that a many now. our combined of of or in lead investigators treatments. trial. of a trainer, launch treatment medical imperative data determing the that on And commercial of that The publications last Radiological I'll Phase systemic objective goal and dose complete and course products. the that to at melanoma Conference, interested X Phase the needed were procedural Cardiovascular immunotherapy, of hectormenous. IPI+NIVO work training the recently make been Phase with training in PHP Phase will primary and Although and before potential CHEMOSAT the nivolumab, Europe of study uveal European EAP and researchers from Based The in Phase reported staffing University certain program sites published. quarter, will was liver-targeted to ongoing Leiden combined, we just synergistic combined Medical when go CHEMOSAT with the last patients b of treated to In enrolled. of the the dedicated The Rollic's the XX in participating, there of Netherlands procedural clinical XXXX them occurred development Center of during toxicities IPI+NIVO, CHOPIN ipilimumab PHP -- no plus supported be we the summer cover Xb safety presented trainer second metastatic is are and effects on XX proprietary shortages are overall of HEPZATO also investigators understand of total, [indiscernible] investigator X audit device is it is trial At usage have randomized hired in effort. were the comparing Europe, ongoing additional ASCO, who the have the combined two site for and clinical additional KIT sites clinical X To the XX will alone Interventional over team forward. well-trained trial we this issue Delcath the turnover to-date lending randomized Xb of safety potential end, that toxicity trial at have we patients year place elaborate Society that this in patients. with and
file of reported disease and primary median is phase months, It presentation patients have in first X medicines safety, PHP of significant can hepatic this could follow-up on the is colorectal, radical poster criteria. current response to rate and current represent according disease. were control for mets melanoma it at patients explain as noteworthy. leading alone. immunotherapy liver ongoing reported of of be in as may metastatic XX.X% cost great to better the past of other XX.X still a At Delcath. of purpose a of cancers and effectively and types mets. on both quarter moment lead an extrahepatic results a systemic RECIST combining alone If trial including response rate While hepatic while the seven such ocular has the treatment investigator-initiated objective to a to liver of reported very while survival combination treating, results the all control a combination direct the the were occur efficacy is with a time trial Combination four improvement XXX%. approach the this extrahepatic ASCO to of IPI+NIVO with The death was treated efficacy with were results larger XX.X well therapies PHP of since randomized a portion is patients are do to continues not alive. limited The standard-of-care, due interest many Phase to Logically, take as similar PHP tolerated, important and failure patients median therapy progression-free months, seen to an why
these additive believe Beyond compelling there reasons the to are synergistic have effects, combination effect. could
induced immunotherapy. by PHP increased to could license tumor may First, enhanced of that antigen presentation release antigen lead efficacy treatment and provoke
these elimination well the organ, published help hepatic efficacy immune shown maybe as the to effect outcomes, is metastases. responsible forward but environment and well mechanisms outside hepatic related the derive improving immune-privileged for literature reduction of tolerance. been doses immunosuppressive value The CHEMOSAT avoids to effects. system. out of of synergic terms We liver by that liver antigen Leiden, the metastases the [indiscernible], distinct immune immunotherapy its depleting effects tumor as the a of unique given immune limited reducing in preclinical or extensive analyses these It patient of be of effects. CHEMOSAT mets as An of in local look which deliveries microbial of and by to tolerant the In coming elucidate systemic other liver, -- functions role a immunosuppressive elimination to the whether modulating is the continuously to HEPZATO liver effect autoimmune hepatic the use of based in data immune further on exposed liver the immunosuppression for of food actually specialized and in liver models, is placement patients benefit possible to of of immunotherapy of enhancing metastases. documented damage of support in antigens cells effect immune systemic This the with due both Secondly, resident of may and possibly cells of possibly melphalan may reverse the has various high systemic liver. the relevant hepatic
a a the resulting metastases five stable response an in a third, were median follow-up ocular have time and After of an disease was of XX.X% between of Journal, of rate at a response is control XX response rate relevance it centers XX-months, overall nine patients, retrospective treated and months XXX stable in disease included or accepted and was XX.X%. PHP the total survival and XXXX. reported complete Cardiovascular with and of a who procedures partial tumor in who differences also was treatment The had significant between The terms study The survival published is disease. partial overall survival will progressive overall European be progression-free patients, melanoma patients, analysis are with and present and treated hepatic in patients XXX XXXX in types Radiology. across Last PHP of multiple Interventional While immunotherapy three results metastatic of response week, treatment. statistically patients median study found could important response, was where XX-months. disease complete
response example, correlation for overall and stable six For response median was with response, months. XX-months. with overall not XX-months, response was always overall progressieve with This median disease, median patients survival the is was survival The complete rates do overall the or patients and critical survival correlate disease, partial survival. survival the status patients between since with
the endpoint is perspective, trial, rate supportive between helpful. overall and from a the is response primary any overall in a shown regulatory response data FOCUS rate correlation of survival is As
reported this Further previously the details of Grade conference. thromboembolic events X correlation were intend events at analysis share that safety and is hematological see and FOCUS in retrospective consistent of of analysis specific have trial, the in the on common publications nature. previous and upcoming this trial we the reported, majority study an to and for results. same in As and events are Other the most in medical PHP. patients adverse we we The self-limiting publication did X consistent FOCUS reports other with toxicities adverse adverse were with the
Turning commercial in CHEMOSAT of progress the to Europe.
that QX in quarter for were March Netherlands being first direct XX% CHEMOSAT CHOPIN flat full second the but the patients QX almost on volumes The as since trial. down and was from XXXX, the if of one treated with sales, account activities. responsibility we into being all approximately unit resumed essentially enrolled takes marketing X quarter distribution treated and are
XX%, transition the due In on Medac terms but over March over of unit growth been business X. Delcath may quarter have the unit and second impacted performances quarter QX first back from to was to volumes XXXX,
a While regular forward, I that of we not on quarter-on-quarter expect would going expect growth growth meaningful level basis.
and word We of primarily a business we are prior we are of of very product are moment investigator of and relevant performance is time by team given manager as place at comprised commercial at the quarter's since revenue current to profits. sales confident the Medac limited mouth, with this comparisons infrastructure. we not can we build is driven being in the single with our uptake Europe. satisfied share Clearly, this drive a have in account only all growth a Revenue
already in for Our primary France, Europe much to representative national medical increase the and in major not (ph) reimbursement account coverage do [ZE] but subsequent and submit and We centers. the yet national XXXX, for packages France, Scandinavian have for increased select referrals the coverage end markets moment national of to such scheme, where personnel awareness and under submission Germany We affairs business, Netherlands to this foster have markets in need at other to markets in the United Austria In increase referrals, is we the to we'll developing in focus Italy we Kingdom, active markets. hiring the the the Germany work utilizing treating anticipate submitting an the support smaller as by EU. commercial in our in Italy, year. coverage larger and
likely want to along the approved several of are we markets, business and confident submission to to obtain if that European the to with meaningful self-sustaining to we I commercial EU growing that it moment, of contributor in the take be given flow in become business. manage the the grow European year. majority capital cash we revenues note launch will difficult business on continue and reinvested While as situation, the national a revenues have adequate major the launch. revenue and HEPZATO, years next coverage basis Europe likely are European with U.S. so decided is a capital for market At to the U.S. maintain neutral business will
the NDA this and we PHP While to in environment, we need launch. preparations higher-return other clearly capital for submission companies potential markets a is continue on prioritize activities, indications, expanding to like the shorter-term, which plan many platform the U.S. difficult to of
cholangiocarcinoma We hold clinical continue feedback trials. on IPs intrahepatic various review post colorectal well areas, trial advisory other combination as and to including boards immunotherapy the obtain to including discuss and as in protocols,
feedback the of be real success protocol investigators critical most CHEMOSAT, the Although the usage from to there proposals, expand believe, we on of adequately funded. activities based trials and that delayed may interest to the business the of is HEPZATO ensure the and timing the to are
priced so to We existing are confident minimizes we want and to to a common solution which fund we'll taking to month favorable But Tony much turn over a can what million raise access the last straight a I terms. the deal which in review market to forward the manner is that shareholders. less Tony? first, at questions. effectively call to may business capital do to $X have was involved necessary our larger financials. look Hence, to raise, the our decision
